Yasushi HARA

Biographic Data

ID5244407
NAMEYasushi HARA
GIVEN NAMESYasushi
FAMILY NAMEHARA
SIGNATUREHARA Y
AFFILIATIONSHitotsubashi University
ORCID0000-0002-0528-3252
VERIFIEDYes
TOTAL WORKS11
TOTAL CITATIONS0
WORKS AS AUTHOR11
WORKS AS EDITOR0
FIRST PUBLICATION YEAR2011
LATEST PUBLICATION YEAR2026
H-INDEX0

  • Innovative Growth and Climate Security

    Open AccessHorst Hanusch, Yasushi HARABOOKInnovative Growth and Climate…2026

  • Effectiveness of Social Measures against Covid-19 Outbreaks in Selected Japanese Regions Analyzed by System Dynamic Modeling

    Open AccessMakoto Niwa, Yasushi HARA et al.ARTICLEInternational Journal of…2020

    In Japan's response to the coronavirus disease 2019 (COVID-19), virus testing was limited to symptomatic patients due to limited capacity, resulting in uncertainty regarding the spread of infection and the appropriateness of countermeasures. System dynamic modelling, comprised of stock flow and infection modelling, was used to describe regional population dynamics and estimate assumed region-specific transmission rates. The estimated regional tra…

  • Industrial development, technology transfer and global competition

    Yasushi HARAARTICLEBusiness History2020

    Industrial development, technology transfer and global competition." Business History, 62(4), pp. 714–715

  • Tocilizumab (Actemra, RoActemra)

    Open AccessYasushi HARA, Yoshiyuki Ohsugi et al.CHAPTERDrug Discovery in Japan2019

  • Donepezil (Aricept)

    Open AccessYasushi HARA, Hideo KawabeCHAPTERDrug Discovery in Japan2019

  • Rosuvastatin (Crestor)

    Open AccessYasushi HARA, Sadao Nagaoka et al.CHAPTERDrug Discovery in Japan2019

  • Nivolumab (Opdivo)

    Open AccessYasushi HARA, Sadao NagaokaCHAPTERDrug Discovery in Japan2019

  • Compactin

    Open AccessSadao Nagaoka, Yasushi HARACHAPTERDrug Discovery in Japan2019

    CompactinCompactin was a breakthrough discovery made by Dr. Akira Endo of Sankyo Co., Ltd. Its discovery enabled the creation of a class of drugs (statins) for hyperlipidemia that effectively and safely lowers cholesterol through competitive inhibition of HMG-CoA reductaseHMG-CoA reductase. This chapter discusses the four major factors that contributed to this breakthrough discovery: (1) the uniqueness of the discovery program, (2) the adoption o…

  • Ofloxacin and Levofloxacin (Tarivid/Cravit)

    Open AccessYasushi HARA, Yuji HonjoCHAPTERDrug Discovery in Japan2019

  • Pravastatin (Pravachol, Mevalotin)

    Open AccessYasushi HARA, Sadao NagaokaCHAPTERDrug Discovery in Japan2019

  • Role of doctoral scientists in corporate R&D in laser diode research in Japan

    Open AccessHiroshi Shimizu, Yasushi HARAARTICLEPrometheus2011

    With the advancement of technology and increase in its complexity, the use of external information and resources provides companies with an important competitive advantage. In addition, the university–industry relationship has received attention with increases in the importance of science. Exploring papers on laser diodes published in Applied Physics Letters and patents from 1960 to 2000, this study analyses the roles of corporate scientists with…